Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.17 USD | +0.87% | +1.06% | +10.75% |
Financials (USD)
Sales 2024 * | 14.91M | Sales 2025 * | 82.05M | Capitalization | 1.41B |
---|---|---|---|---|---|
Net income 2024 * | -247M | Net income 2025 * | -202M | EV / Sales 2024 * | 81.6 x |
Net cash position 2024 * | 196M | Net cash position 2025 * | 212M | EV / Sales 2025 * | 14.6 x |
P/E ratio 2024 * |
-5.75
x | P/E ratio 2025 * |
-7.56
x | Employees | 174 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.32% |
Latest transcript on Day One Biopharmaceuticals, Inc.
1 day | +0.87% | ||
1 week | +1.06% | ||
Current month | -5.44% | ||
1 month | +2.67% | ||
3 months | +5.48% | ||
6 months | +33.20% | ||
Current year | +10.75% |
Managers | Title | Age | Since |
---|---|---|---|
Samuel Blackman
FOU | Founder | 55 | 18-10-31 |
Jeremy Bender
CEO | Chief Executive Officer | 52 | 20-08-31 |
Charles York
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 21-08-16 |
Natalie Holles
BRD | Director/Board Member | 51 | 21-01-31 |
John Josey
BRD | Director/Board Member | 63 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.04% | 1,487 M€ | +9.17% | - | |
0.01% | 9 M€ | +11.05% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 16.17 | +0.87% | 421,575 |
24-05-16 | 16.03 | -2.38% | 491,717 |
24-05-15 | 16.42 | -1.20% | 571,842 |
24-05-14 | 16.62 | +3.55% | 331,987 |
24-05-13 | 16.05 | +0.31% | 467,496 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.75% | 1.41B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- DAWN Stock